Literature DB >> 28377069

Inflammatory cytokines and angiogenic factors as potential biomarkers in South African pancreatic ductal adenocarcinoma patients: A preliminary report.

Yandiswa Y Yako1, Martin Brand2, Martin Smith2, Deirdré Kruger3.   

Abstract

BACKGROUND/
OBJECTIVES: Several studies have investigated the association of differentially expressed cytokines with pancreatic ductal adenocarcinoma (PDAC), but none in African countries. This study aimed at investigating T-helper (Th) cell and angiogenic markers as diagnostic or prognostic biomarkers for PDAC in Black South Africans.
METHODS: We conducted a prospective, case-control study comprising of 34 PDAC patients and 27 control participants with either critical limb ischemia, abdominal aortic aneurysm or other abdominal pathology from causes other than pancreatic disease. Plasma levels of IL-2, IL-4, IL-6, IL-10, TNF, IFN-γ, IL-17A, VEGF, sVEGF-R1, FGF, PIGF, PDGF and P-selectin were measured using commercially available cytometric bead array, ELISA and multi-analyte Luminex kits.
RESULTS: Significantly higher levels of IFN-γ (p < 0.001), TNF (p < 0.001), IL-2 (p = 0.001), IL-4 (p < 0.01), IL-10 (p < 0.01), IL-17A (p < 0.01), PlGF (p < 0.0001) and basic FGF (p < 0.0001) were found in cases compared to control participants. PDAC patients with irresectable tumours had higher levels of VEGF (p = 0.02) and IL-6 (p = 0.01). A univariate analysis showed significant associations between IFN-γ, TNF, IL-10, -4, -2, basic FGF, PlGF and PDAC. In a multivariate logistic regression model, basic FGF (p = 0.002) and PlGF (p = 0.007) were independent risk factors for PDAC with a combined sensitivity of 71% and specificity of 100%.
CONCLUSION: Our preliminary data suggests a potential role for basic FGF and PlGF as diagnostic, and VEGF and IL-6 as prognostic biomarkers of PDAC in Black South African patients.
Copyright © 2017 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cytokines; Pancreatic ductal adenocarcinoma; South Africa

Mesh:

Substances:

Year:  2017        PMID: 28377069     DOI: 10.1016/j.pan.2017.03.003

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  5 in total

1.  Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: Enhancing diagnostic accuracy.

Authors:  Deirdré Kruger; Yandiswa Y Yako; John Devar; Nicola Lahoud; Martin Smith
Journal:  PLoS One       Date:  2019-08-15       Impact factor: 3.240

2.  Pancreatic ductal adenocarcinoma: Prognostic indicators of advanced disease.

Authors:  Deirdré Kruger; Nicola Lahoud; Yandiswa Y Yako; John Devar; Martin Smith
Journal:  PLoS One       Date:  2022-01-12       Impact factor: 3.240

3.  Validation of IL-7R as an Immunological Biomarker for Human Pancreatic Ductal Adenocarcinoma.

Authors:  Sung-Ill Jang; Jae-Hee Cho; So-Young Kim; In-Young Hong; Joon-Seong Park; Hye-Sun Lee; Goeun Park; Jong-Kyoung Kim; Hyung-Keun Lee; Dong-Ki Lee
Journal:  Cancers (Basel)       Date:  2022-02-08       Impact factor: 6.639

4.  Genetic Mutations Associated with Hormone-Positive Breast Cancer in a Small Cohort of Ethiopian Women.

Authors:  Alyssa D Schwartz; Afua Adusei; Solomon Tsegaye; Christopher A Moskaluk; Sallie S Schneider; Manu O Platt; Daniel Seifu; Shelly R Peyton; Courtney C Babbitt
Journal:  Ann Biomed Eng       Date:  2021-06-17       Impact factor: 3.934

Review 5.  Involvement of IL-4, IL-13 and Their Receptors in Pancreatic Cancer.

Authors:  Jingwei Shi; Xujun Song; Benno Traub; Michael Luxenhofer; Marko Kornmann
Journal:  Int J Mol Sci       Date:  2021-03-15       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.